- Home
- FSK vs IONS Comparison
FSK vs IONS Comparison
Compare FSK & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSK
- IONS
- Stock Information
- Founded
- FSK 2007
- IONS 1989
- Country
- FSK United States
- IONS United States
- Employees
- FSK N/A
- IONS N/A
- Industry
- FSK Investment Managers
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- FSK Finance
- IONS Health Care
- Exchange
- FSK Nasdaq
- IONS Nasdaq
- Market Cap
- FSK 6.0B
- IONS 6.0B
- IPO Year
- FSK N/A
- IONS 1991
- Fundamental
- Price
- FSK $21.30
- IONS $36.17
- Analyst Decision
- FSK Hold
- IONS Buy
- Analyst Count
- FSK 9
- IONS 18
- Target Price
- FSK $20.00
- IONS $62.00
- AVG Volume (30 Days)
- FSK 1.6M
- IONS 1.7M
- Earning Date
- FSK 11-06-2024
- IONS 02-19-2025
- Dividend Yield
- FSK 13.15%
- IONS N/A
- EPS Growth
- FSK N/A
- IONS N/A
- EPS
- FSK 1.89
- IONS N/A
- Revenue
- FSK $1,761,000,000.00
- IONS $803,067,000.00
- Revenue This Year
- FSK N/A
- IONS N/A
- Revenue Next Year
- FSK N/A
- IONS $19.61
- P/E Ratio
- FSK $11.29
- IONS N/A
- Revenue Growth
- FSK N/A
- IONS 30.57
- 52 Week Low
- FSK $18.31
- IONS $33.33
- 52 Week High
- FSK $22.39
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- FSK 49.67
- IONS 41.84
- Support Level
- FSK $20.94
- IONS $36.39
- Resistance Level
- FSK $21.49
- IONS $38.90
- Average True Range (ATR)
- FSK 0.28
- IONS 1.52
- MACD
- FSK -0.08
- IONS -0.08
- Stochastic Oscillator
- FSK 30.51
- IONS 6.61
About FSK FS KKR Capital Corp.
FS KKR Capital Corp is a business development company based in the United States. Its portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies. It is focused on providing customized credit solutions to private upper middle-market companies, which it generally defines as companies with annual EBITDA of at least $50 million at the time of investment.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.